Xbiotech
XBIT

Xbiotech (XBIT) news

Recent news

Xbiotech announces election of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers

XBiotech Inc. has announced the election of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective immediately. This leadership change marks a strategic shift for the biotechnology company as it continues to navigate its business and operational landscape. The decision…

AInvest Wire · Oct 23, 2026

Xbiotech - Vilamakitug showed 62% reduction in risk of death in right-sided tumors

AInvest Wire · Oct 19, 2026

Xbiotech - 44 of 79 patients (55.7%) in control arm alive at 12 months

XBiotech Inc. (NASDAQ: XBIT) has reported that 44 of 79 patients (55.7%) in the control arm of its clinical trial were alive at 12 months. This data point provides insight into the baseline survival rate for patients not receiving the experimental treatment, which is essential for evaluating the…

AInvest Wire · Oct 19, 2026

Xbiotech - Announces positive final efficacy results from phase II taskin trial

Xbiotech recently announced the release of final efficacy results from its Phase II TASKIN trial, which evaluated the investigational monoclonal antibody Xilonix (anti-TNFα) in patients with severe sepsis and septic shock. The trial, conducted across multiple international sites, aimed to assess…

AInvest Wire · Oct 19, 2026

Xbiotech Vilamakitug cuts death risk 62% in right-sided tumors

Xbiotech's Vilamakitug, an anti-IL1F1 monoclonal antibody, has demonstrated a significant reduction in mortality risk for patients with right-sided tumors, according to recent clinical findings. Specifically, the treatment was associated with a 62% decrease in the risk of death compared to…

AInvest Wire · Oct 19, 2026

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.